Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Life Sciences and Cephalon Awarded US Patents

Enzo Life Sciences has been awarded US Patent 7,256,299, “Chemiluminescent reagents.”
The inventors listed on the patent are Jannis Stavrianopoulos and Elazar Rabbani.
This invention provides for labeling reagents, labeled targets, and processes for preparing labeling reagents, the abstract said. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes, or composite dyes. As stated in the abstract, these labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe-based assays. They are also applicable to real-time detection processes.

Cephalon has been awarded US Patent 7,256,252, “Methods for detecting cell apoptosis.”
Inventors listed on the patent are Robert Siman, Donna Bozyczko-Coyne, and Sheryl Meyer.
The abstract said that the invention describes methods for the biochemical and immunohistochemical detection of cell apoptosis. The methods utilize the detection and measurement of polypeptide fragments generated during apoptosis. According to the abstract, conditions associated with apoptosis may be detected by the methods of this invention. Methods are also presented for the screening of potential therapeutic compounds which inhibit or stimulate apoptosis. Kits for detection of apoptosis and diagnosis of diseases are also provided.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.